biostudies-literatureTurner NCHHS | NIH | National Cancer InstituteNCI NIH HHS5482-5491https://www.ebi.ac.uk/biostudies/studies/S-EPMC8530899biostudies-literatureUnknown27(20)<h4>Purpose</h4>To investigate the activity of niraparib in patients with germline-mutated <i>BRCA1/2</i> (g<i>BRCA</i>m) advanced breast cancer.<h4>Patients and methods</h4>BRAVO was a randomized, open-label phase III trial. Eligible patients had g<i>BRCA</i>m and HER2-negative advanced breast cancer previously treated with ≤2 prior lines of chemotherapy for advanced breast cancer or had relapsed within 12 months of adjuvant chemotherapy, and were randomized 2:1 between niraparib and physician's choice chemotherapy (PC; monotherapy with eribulin, capecitabine, vinorelbine, or gemcitabine). Patients with hormone receptor-positive tumors had to have received ≥1 line of endocrine therapy and progressed during this treatment in the metastatic setting or relapsed within 1 year of (neo)adjuvantClinical cancer research : an official journal of the American Association for Cancer ResearchNiraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study.PMC8530899U10 CA027525P30 CA006927P30CA006927Tutt ANKaufman BGoldstein LJZoppoli GEllard SLLitiere SManso LJohannsson OTLang IHonkoop AHTurner NCJuan-Fita MJMusolino AVuylsteke PErban JAudeh WBRAVO Steering Committee and the BRAVO investigatorsTredan OMailliez APoncet CTryfonidis KCameron DAColleoni MMacpherson IRJJen KYRazis EIgnatiadis MGoulioti TBalmana JAdam VfalseNiraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study.<h4>Purpose</h4>To investigate the activity of niraparib in patients with germline-mutated <i>BRCA1/2</i> (g<i>BRCA</i>m) advanced breast cancer.<h4>Patients and methods</h4>BRAVO was a randomized, open-label phase III trial. Eligible patients had g<i>BRCA</i>m and HER2-negative advanced breast cancer previously treated with ≤2 prior lines of chemotherapy for advanced breast cancer or had relapsed within 12 months of adjuvant chemotherapy, and were randomized 2:1 between niraparib and physician's choice chemotherapy (PC; monotherapy with eribulin, capecitabine, vinorelbine, or gemcitabine). Patients with hormone receptor-positive tumors had to have received ≥1 line of endocrine therapy and progressed during this treatment in the metastatic setting or relapsed within 1 year of (neo)adjuvant2021-01-01T00:00:00Z2021 Oct2026-05-07T22:20:20.342Z2025-02-19T03:53:27.962ZS-EPMC85308993430174910.1158/1078-0432.CCR-21-0310